AG490 influences UCN-01 (cas 112953-11-4)-induced cytotoxicity in Glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation
-
Add time:08/01/2019 Source:sciencedirect.com
We determined the cytotoxicity of AG490 as a single agent and in combination with 7-hydroxystaurosporine (UCN-01) in a panel of malignant human glioma cell lines. Because p53 has important roles in cell cycle checkpoints, it has been anticipated that modulation of checkpoint pathways should sensitize p53 defective cells while sparing the normal cells. Cell proliferation was determined from dose–response curves. AG490 was effective as a cytotoxic agent alone regardless of p53 status. Combining the Chk1 inhibitor UCN-01 dramatically enhanced the response to AG490 in p53-mutated or deleted glioma cells. An opposite effect was noted in p53-wild type cells, in which UCN-01 and AG490 had antagonistic effects on cell proliferation and viability. We found that AG490 enhanced BAD phosphorylation in p53 wild type glioma cells, which appeared to protect against UCN-01-induced cytotoxicity, whereas AG490 enhanced UCN-01-induced cytotoxicity in p53 defective cell lines by suppression of BAD phosphorylation and induction of BAX and PARP cleavage. These observations highlight the potential for genotype-dependent factors to strongly influence response to signaling-targeted therapies in malignant gliomas and the importance of considering such factors in correlative response analyses for these agents.
We also recommend Trading Suppliers and Manufacturers of UCN-01 (cas 112953-11-4). Pls Click Website Link as below: cas 112953-11-4 suppliers
Prev:Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 (cas 112953-11-4) in human plasma
Next:Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 (cas 112953-11-4), in human plasma or urine) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- UCN-01 (cas 112953-11-4), an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily08/05/2019
- Controlled release of a protein kinase inhibitor UCN-01 (cas 112953-11-4) from liposomes influenced by the particle size08/04/2019
- UCN-01 (cas 112953-11-4) in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium08/03/2019
- Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 (cas 112953-11-4), in human plasma or urine08/02/2019
- Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 (cas 112953-11-4) in human plasma07/31/2019
- MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 (cas 112953-11-4) by exacerbating radiation-induced aberrant mitosis07/30/2019
- The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01 (cas 112953-11-4), induces fragmentation: Possible role of metalloproteinases07/29/2019
- Celecoxib Enhances the Radiosensitizing Effect of 7-Hydroxystaurosporine (UCN-01 (cas 112953-11-4)) in Human Lung Cancer Cell Lines07/28/2019
- The combination of UCN-01 (cas 112953-11-4) and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK07/27/2019